Clinical Trials Logo

Filter by:
NCT ID: NCT00476892 Completed - Clinical trials for Pelvic Organ Prolapse

Multi-centre Randomised Controlled Trial of Pelvic Floor Muscle Training for Prolapse

POPPY
Start date: June 2007
Phase: N/A
Study type: Interventional

The aim of this study is to determine the effectiveness and cost-effectiveness of pelvic floor muscle training in the management of pelvic organ prolapse in women.

NCT ID: NCT00476034 Completed - Osteoarthritis Clinical Trials

Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)

Start date: December 2003
Phase: Phase 3
Study type: Interventional

This 39-week, active controlled, study is designed to assess long-term efficacy, safety and tolerability of lumiracoxib 100mg od in patients with osteoarthritis (OA) of the knee who participated in the 13-week core CCOX189A2361 study.

NCT ID: NCT00475852 Completed - Clinical trials for Heart Decompensation

A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure

Start date: May 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to find out if nesiritide (a human B-type natriuretic peptide/hBNP) as compared to placebo, plus the usual treatment for acute decompensated heart failure, helps to improve breathing difficulties, reduce heart failure readmissions to hospitals, and helps patients live longer.

NCT ID: NCT00474058 Completed - Parkinson's Disease Clinical Trials

Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

RECOVER
Start date: May 2007
Phase: Phase 3
Study type: Interventional

The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease. In addition, effects of rotigotine on specific nocturnal and non-motor symptoms of Parkinson´s disease will be evaluated.

NCT ID: NCT00469456 Completed - Alzheimer's Disease Clinical Trials

Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease

Start date: April 2007
Phase: Phase 4
Study type: Interventional

The objective of this study is to evaluate the effect of memantine versus placebo on functional communication in patients with Alzheimer's Disease

NCT ID: NCT00463788 Completed - Breast Neoplasm Clinical Trials

Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer

BALI-1
Start date: June 2007
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine whether overall response to cetuximab combined with cisplatin is better than overall response to cisplatin alone together with showing that the overall response for cetuximab and cisplatin was above a pre-specified threshold of 0.2 in the treatment of "triple negative" metastatic breast cancer. The secondary objective of this study is to compare the differences between the two treatment groups using the following criteria : Progression-Free Survival (PFS) Time, Overall Survival (OS), Time to Response (TTR) and Safety.

NCT ID: NCT00461409 Completed - Seizures Clinical Trials

IV Levetiracetam for the Treatment of Neonatal Seizures: a Pharmacokinetic and Preliminary Efficacy and Safety Study

Start date: April 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the correct dosing for intravenous levetiracetam in term new born babies with seizures. In addition information on safety and efficacy will be collected. This new anticonvulsant drug is a promising treatment for seizures in newborns.

NCT ID: NCT00459836 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors

Start date: February 2007
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as PR-104, docetaxel, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of PR-104 when given together with docetaxel or gemcitabine in treating patients with solid tumors.

NCT ID: NCT00455130 Completed - Cystic Fibrosis Clinical Trials

A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis

Start date: March 2004
Phase: Phase 2
Study type: Interventional

Cystic fibrosis is the most frequent lethal genetic disease of childhood. Causes disruption of glandular function of the pancreas, intestine, liver, lungs (causing chronic lung infection with emphysema), sweat glands and reproductive organs. We know that many CF patients die of lung failure, brought about in part by repeated lung infections caused by thick, sticky mucus that cannot be readily cleared from the lung. Inhaled mannitol is an osmotic agent that has been investigated in a number of small studies that have examined mucociliary clearance, quality of life and lung function in CF and bronchiectasis. The promising results of these studies warrant futher investigation. The aim of this study is to assess the safety and efficacy of inhaled mannitol when administered twice a day over two weeks in CF.

NCT ID: NCT00453999 Completed - Influenza Clinical Trials

Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza

Start date: July 2007
Phase: Phase 2
Study type: Interventional

This study has been designed as a randomized, double-blind, controlled, study to evaluate the efficacy and safety of two once daily intravenous peramivir regimens (200 mg and 400 mg) versus oral oseltamivir phosphate (75 mg twice daily) in hospitalized subjects with acute serious or potentially life threatening influenza. Study treatments will be provided for up to 5 consecutive days.